PRAME Expression in Hairy Cell Leukemia

Overview

Journal Leuk Res

Date 2008 Feb 26

PMID 18295331

Citations 3

Authors

Evgeny Arons

Tara Suntum

Inger Margulies

Constance Yuan

Maryalice Stetler-Stevenson

Robert J Kreitman

Affiliations

Soon will be listed here.

Abstract

PRAME has been proposed as a useful marker for solid tumors and acute B-cell malignancies. Several studies demonstrate expression in CLL. To further examine its B-cell tumor distribution, we studied PRAME in both CLL and hairy cell leukemia (HCL). While by conventional PCR only 8% of 37 HCL and 27% of 22 CLL patients were positive, nearly all patients and normal donors expressed PRAME by real-time quantitative (TaqMan) PCR. We conclude that HCL and CLL differ in PRAME overexpression, and that basal normal expression of PRAME may limit its usefulness for following patients with minimal residual CLL or HCL.

Citing Articles

PRAME Updated: Diagnostic, Prognostic, and Therapeutic Role in Skin Cancer.

Cassalia F, Danese A, Tudurachi I, Federico S, Zambello A, Guidotti A Int J Mol Sci. 2024; 25(3).

PMID: 38338862 PMC: 10855739. DOI: 10.3390/ijms25031582.

Lack of PRAME Expression in Cutaneous T-Cell Lymphomas.

Bui C, Kitahara S, Shon W, Pukhalskaya T, Smoller B Dermatopathology (Basel). 2022; 9(1):11-16.

PMID: 35076507 PMC: 8788415. DOI: 10.3390/dermatopathology9010002.

Tumour-associated antigens: considerations for their use in tumour immunotherapy.

Linley A, Ahmad M, Rees R Int J Hematol. 2011; 93(3):263-273.

PMID: 21360066 DOI: 10.1007/s12185-011-0783-1.

References

Goodman G, Bethel K, Saven A . Hairy cell leukemia: an update. Curr Opin Hematol. 2003; 10(4):258-66. DOI: 10.1097/00062752-200307000-00002. View

Tajeddine N, Millard I, Gailly P, Gala J . Real-time RT-PCR quantification of PRAME gene expression for monitoring minimal residual disease in acute myeloblastic leukaemia. Clin Chem Lab Med. 2006; 44(5):548-55. DOI: 10.1515/CCLM.2006.106. View

Proto-Siqueira R, Figueiredo-Pontes L, Panepucci R, Garcia A, Rizzatti E, Nascimento F . PRAME is a membrane and cytoplasmic protein aberrantly expressed in chronic lymphocytic leukemia and mantle cell lymphoma. Leuk Res. 2006; 30(11):1333-9. DOI: 10.1016/j.leukres.2006.02.031. View

Roman-Gomez J, Jimenez-Velasco A, Agirre X, Castillejo J, Navarro G, Jose-Eneriz E . Epigenetic regulation of PRAME gene in chronic myeloid leukemia. Leuk Res. 2007; 31(11):1521-8. DOI: 10.1016/j.leukres.2007.02.016. View

Oberthuer A, Hero B, Spitz R, Berthold F, Fischer M . The tumor-associated antigen PRAME is universally expressed in high-stage neuroblastoma and associated with poor outcome. Clin Cancer Res. 2004; 10(13):4307-13. DOI: 10.1158/1078-0432.CCR-03-0813. View

Schenk T, Stengel S, Goellner S, Steinbach D, Peter Saluz H . Hypomethylation of PRAME is responsible for its aberrant overexpression in human malignancies. Genes Chromosomes Cancer. 2007; 46(9):796-804. DOI: 10.1002/gcc.20465. View

Paydas S, Tanriverdi K, Yavuz S, Seydaoglu G . PRAME mRNA levels in cases with chronic leukemia: Clinical importance and review of the literature. Leuk Res. 2006; 31(3):365-9. DOI: 10.1016/j.leukres.2006.06.022. View

Greiner J, Ringhoffer M, Taniguchi M, Li L, Schmitt A, Shiku H . mRNA expression of leukemia-associated antigens in patients with acute myeloid leukemia for the development of specific immunotherapies. Int J Cancer. 2003; 108(5):704-11. DOI: 10.1002/ijc.11623. View

Kamiguti A, Serrander L, Lin K, Harris R, Cawley J, Allsup D . Expression and activity of NOX5 in the circulating malignant B cells of hairy cell leukemia. J Immunol. 2005; 175(12):8424-30. DOI: 10.4049/jimmunol.175.12.8424. View

10.

Steinbach D, Hermann J, Viehmann S, Zintl F, Gruhn B . Clinical implications of PRAME gene expression in childhood acute myeloid leukemia. Cancer Genet Cytogenet. 2002; 133(2):118-23. DOI: 10.1016/s0165-4608(01)00570-2. View

11.

Spanaki A, Perdikogianni C, Linardakis E, Kalmanti M . Quantitative assessment of PRAME expression in diagnosis of childhood acute leukemia. Leuk Res. 2006; 31(5):639-42. DOI: 10.1016/j.leukres.2006.06.006. View

12.

Willenbrock K, Kuppers R, Renne C, Brune V, Eckerle S, Weidmann E . Common features and differences in the transcriptome of large cell anaplastic lymphoma and classical Hodgkin's lymphoma. Haematologica. 2006; 91(5):596-604. View

13.

Kreitman R, Wilson W, Bergeron K, Raggio M, Stetler-Stevenson M, Fitzgerald D . Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med. 2001; 345(4):241-7. DOI: 10.1056/NEJM200107263450402. View

14.

Matsushita M, Ikeda H, Kizaki M, Okamoto S, Ogasawara M, Ikeda Y . Quantitative monitoring of the PRAME gene for the detection of minimal residual disease in leukaemia. Br J Haematol. 2001; 112(4):916-26. DOI: 10.1046/j.1365-2141.2001.02670.x. View

15.

Doolan P, Clynes M, Kennedy S, Mehta J, Crown J, ODriscoll L . Prevalence and prognostic and predictive relevance of PRAME in breast cancer. Breast Cancer Res Treat. 2007; 109(2):359-65. DOI: 10.1007/s10549-007-9643-3. View

16.

Partheen K, Levan K, Osterberg L, Horvath G . Expression analysis of stage III serous ovarian adenocarcinoma distinguishes a sub-group of survivors. Eur J Cancer. 2006; 42(16):2846-54. DOI: 10.1016/j.ejca.2006.06.026. View

17.

Vanhentenrijk V, Tierens A, Wlodarska I, Verhoef G, Wolf-Peeters C . V(H) gene analysis of hairy cell leukemia reveals a homogeneous mutation status and suggests its marginal zone B-cell origin. Leukemia. 2004; 18(10):1729-32. DOI: 10.1038/sj.leu.2403503. View

18.

Steinbach D, Viehmann S, Zintl F, Gruhn B . PRAME gene expression in childhood acute lymphoblastic leukemia. Cancer Genet Cytogenet. 2002; 138(1):89-91. DOI: 10.1016/s0165-4608(02)00582-4. View

19.

Van Baren N, Chambost H, Ferrant A, Michaux L, Ikeda H, Millard I . PRAME, a gene encoding an antigen recognized on a human melanoma by cytolytic T cells, is expressed in acute leukaemia cells. Br J Haematol. 1998; 102(5):1376-9. DOI: 10.1046/j.1365-2141.1998.00982.x. View

20.

Arons E, Margulies I, Sorbara L, Raffeld M, Stetler-Stevenson M, Pastan I . Minimal residual disease in hairy cell leukemia patients assessed by clone-specific polymerase chain reaction. Clin Cancer Res. 2006; 12(9):2804-11. DOI: 10.1158/1078-0432.CCR-05-2315. View